AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

Contract Categories: Human Resources - Employment Agreements
EX-10.2 3 a05-6920_1ex10d2.htm EX-10.2

EXHIBIT 10.2

 

AMENDMENT
TO
EXECUTIVE EMPLOYMENT AGREEMENT

 

This First Amendment to the Executive Employment Agreement (this “Amendment”) is dated April 13, 2004 and is made by and among Bioject Inc. (“BI”) and Bioject Medical Technologies Inc. (“BMT”) (collectively, “Employer”), and J. Michael Redmond, an individual (“Executive”) (together the “Parties”).

 

RECITALS

 

WHEREAS, the Parties entered into an Executive Employment Agreement on or about March 13, 2003 (the “Employment Agreement”); and

 

WHEREAS, the Parties now want to amend the Employment Agreement to provide certain additional benefits to Executive and to make such changes as are specifically covered herein.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, and in consideration of the mutual covenants and conditions herein set forth, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

1.                                      Restricted Stock Unit Award.  Following the execution of this Amendment by the Parties (the “Effective Date”), BMT will grant Executive a restricted stock unit award (the “Award”) under the Bioject Restated 1992 Stock Incentive plan, as amended September 13, 2001 and March 13, 2003 (the “Plan”), with each unit representing the right to receive one share of BMT Common Stock, subject to certain vesting conditions and forfeiture provisions. Following the Effective Date, BMT will provide Executive with a Restricted Stock Unit Grant Agreement that evidences the Award.  The Restricted Stock Unit Grant Agreement sets forth the specific terms and conditions of the Award, including, without limitation, the certain time and performance-based vesting conditions as well as the terms under which Executive will forfeit the Award (including termination of Executive’s employment with Employer).  The Award is subject to Board approval and Executive’s execution of the Restricted Stock Unit Grant Agreement and this Amendment.

 

2.                                      Compliance with Company Policies; Applicable Legal Requirements.  Executive shall comply with the Company’s policies and procedures to the extent they are not inconsistent with the Employment Agreement, as amended by this Amendment, in which case the provisions of the Employment Agreement, as amended, shall prevail.  Executive shall comply with all legal requirements applicable to Executive’s position, including without limitation, requirements arising out of the Sarbanes-Oxley Act of 2002.

 

3.                                      Stock Options.  Section 5 of the Employment Agreement shall be amended by adding new Sections 5.3, 5.4 and 5.5, as set forth below:

 

“5.3                           Stock Options.  In the event of a (A) termination of Executive’s employment pursuant to Section 4.5 (Change of Control), or (B) termination of Executive’s employment pursuant to

 

1



 

Section 4.2(a) (ii)(including deemed termination pursuant to Section 4.1 (Term), subject to Executive’s compliance with the requirements set forth in Section 5.5 below, all stock options which have been previously awarded to Executive, but are not yet vested, will be 100% vested on the Effective Date of the Release of Claims (as those terms are defined in Section 5.5, below).  Notwithstanding the foregoing, all the other conditions and restrictions in the Incentive Stock Option Agreement and the Bioject Medical Technologies Inc. Restated 1992 Stock Incentive Plan, as amended September 13, 2001 and March 13, 2003, shall remain in effect.”

 

5.4                                 Restricted Stock Units.  In the event of termination of Executive’s employment pursuant to Section 4.2(a)(ii) (including deemed termination pursuant to Section 4.1) of the Employment Agreement, subject to Executive’s compliance with the requirements set forth in Section 5.5, below and notwithstanding the forfeiture provisions of Section 3(c) of Executive’s Restricted Stock Unit Grant Agreement, all Restricted Stock Units that have been previously awarded to Executive will immediately be deemed earned and 100% vested on the Effective Date of the Release of Claims (as those terms are defined in Section 5.5, below).  All the other conditions and restrictions in the Restricted Stock Unit Grant Agreement and Notice of Grant shall remain in effect, including without limitation, the Executive’s obligation to pay the Company such amount of cash as the Company may require, under all applicable federal, state, local or other laws or regulations, to withhold and pay over as income or other withholding taxes for all Restricted Stock Units which vest on the Effective Date of the Release of Claims.

 

5.5                                 Release of Claims.  As a condition precedent to the accelerated vesting of stock options pursuant to Section 5.3, above and restricted stock units pursuant to Section 5.4, above, Executive shall be required to sign, deliver to the Company and not revoke a release of claims in a form to be provided by the Company at the time of termination (the “Release of Claims”).   Such accelerated vesting of stock options and restricted stock units shall be effective on the eighth (8th) day after delivery of the executed Release of Claims by Executive to the Company, provided that Executive has not revoked acceptance or rescinded the Release of Claims (the “Effective Date”).”

 

5.                                      Confidentiality and Invention Ownership Agreement.  Concurrent with the execution of this Agreement, Employee has also entered into and agreed to be bound by the terms of that certain Bioject Inc. Employee Confidentiality and Invention Ownership Agreement, a copy of which is attached as Attachment 1, and incorporated herein by this reference.

 

6.                                      Disclosure of Information and Employee Restrictions.  Section 6.1 c. is modified by deleting the words in line two:  “for five years.”

 

7.                                      Amendment to Employment Agreement; Order of Precedence.  This Amendment constitutes an amendment to the Employment Agreement between the Parties, within the meaning of Section 6.6 of the Employment Agreement.  Except as set forth in this Amendment, the Employment Agreement shall remain in full force and effect and references in the Employment Agreement to “this Agreement”, “hereunder,” “herein,” “hereof,” and words of like effect shall mean the Employment Agreement as so amended by this Amendment.  In the event of any conflicts between the provisions contained in this Amendment and the provisions of the Employment Agreement, the provisions contained in this Amendment shall prevail. Any defined terms used in the Employment Agreement which are wholly or partially redefined by this Amendment shall be interpreted in such Employment Agreement as being so redefined.

 

2



 

8.                                      CounterpartsThis Amendment may be executed in one or more counterparts and/or by facsimile, each of which shall be deemed an original and all of which signed, taken together, shall constitute one instrument.

 

IN WITNESS WHEREOF, the Parties have executed this Amendment effective on the day and year first written above.

 

ACCEPTED AND AGREED:

 

 

 

 

 

 

 

 

/s/ J. Michael Redmond

 

 

 

J. Michael Redmond, Executive

 

 

 

 

 

 

 

 

BIOJECT, INC.

 

BIOJECT MEDICAL TECHNOLOGIES INC.

 

 

 

 

 

 

By:

/s/ Christine Farrell

 

 

By:

Christine Farrell

 

 

 

 

Name:

Christine Farrell

 

 

Name:

Christine Farrell

 

 

 

 

Title:

Corporate Controller

 

 

Title:

Corporate Controller

 

 

3